Tag: PICO strategy
What Can We Learn from the First Three EU Joint Clinical Assessment (JCA) Reports?
What Can We Learn from the First Three EU Joint Clinical Assessment (JCA) Reports? The European Union’s Health Technology Assessment (HTA) Regulation has entered a new era. In just a few months, the European Commission has published the first three official Joint Clinical Assessment (JCA) reports, providing pharmaceutical companies with the clearest indication yet of…
Evidence Generation Is No Longer Enough: Why Evidence Prioritisation Is Pharma’s Next Competitive Advantage
Evidence Generation Is No Longer Enough: Why Evidence Prioritisation Is Pharma’s Next Competitive Advantage in the EU HTA Era The Industry Has Moved Beyond Generating More Evidence For years, pharmaceutical innovation has focused on answering one fundamental question: “Do we have enough evidence to secure regulatory approval?” Today, that question has evolved. Across Europe, Market…
Overcoming ‘PICO Anxiety’: How Biopharma Can Master the New European HTA Era
Overcoming ‘PICO Anxiety’: How Biopharma Can Master the New European HTA Era The European pharmaceutical market access landscape is entering a new phase. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation, Joint Clinical Assessments (JCA) are becoming an integral part of evidence planning for eligible medicines across Europe. As mandatory…
